Recent Updates
Recently added Catalysts

FXR 450

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Mar 13, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment64
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00499629Study Evaluating the Safety of FXR-450 in Healthy SubjectsPHASE1 COMPLETED 64Oct 1, 2007Feb 1, 2008Mar 13, 20081 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety, tolerability
4 days
Secondary Endpoints
pharmacokinetics
4 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
Treatment Arms
ArmTypeDescription
1ACTIVE_COMPARATORArm 1: FXR 450
2PLACEBO_COMPARATORPlacebo
Interventions
NameTypeDescription
FXR 450DRUGcapsule, single oral doses from 10 mg to 450 mg
placeboDRUGcapsule similar to active drug
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 50 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Men or women of nonchildbearing potential (WONCBP) aged 18 to 50 years inclusive at screening. * Healthy as determined by the investigator on the basis of screening evaluations. * Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must be able to...

Countries:United States
Unlock Eligibility Criteria